New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

Updated March 1st, 2022

New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA

The FDA has approved PARP Inhibitor Olaparib for the treatment of advanced prostate cancer patients. Experts say this approval marks new personalized therapy options for specific tumors.

NOW
PLAYING
It is important to prepare for your cancer journey. Ask your doctor the right questions for each step.
NOW
PLAYING
Colon cancer is a type of cancer that affects your large intestine (colon) or the end of your intestine (rectum).
NOW
PLAYING
Prostate Cancer Treatment in Five Days? Everything You Need to Know.
NOW
PLAYING
Psoriatic Arthritis Flare-Up in Feet
NOW
PLAYING
Can Psoriasis Affect Your Eyes?
NOW
PLAYING
Psoriasis Healing Signs

Later Stage Treatment: New Treatment Developments

SEE MORE   

  • There are several new drugs and treatment options available for those facing advanced stage prostate cancer.
  • Two PARP inhibitors are currently FDA-approved: Lynparza (olaparib) and Rubraca (rucaparib).
  • Two newer androgen deprivation therapies include: Xtandi (enzalutamide) Erleada (apalutamide).

Later Stage Treatment: New Treatment Developments

  • There are several new drugs and treatment options available for those facing advanced stage prostate cancer.
  • Two PARP inhibitors are currently FDA-approved: Lynparza (olaparib) and Rubraca (rucaparib).
  • Two newer androgen deprivation therapies include: Xtandi (enzalutamide) Erleada (apalutamide).
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.